Reyes CA, Capó de PV, Díaz JM, Pérez ÁJ, Bouza JY

Language: Spanish
References: 24
Page: 195-201
PDF size: 81.97 Kb.

ABSTRACT

Background: HIV infection affects 0.09% of Cuban adults; it is related to 5.1% of tuberculosis (TB) cases diagnosed each year. The objective of this study was to characterize the clinical and immuno-virological response of HIV-1 positive individuals infected with TB in Cuba.
Methods: Longitudinal study of a cohort of 35 HIV positive individuals infected with TB, followed for a year. We analyzed demographic, clinical and therapeutic response variables, CD4+TC count and HIV-1 plasma viral load (PVL).
Results: Males 77.1%, mean age 35 years. Five patients had clinical evidences of the immunological reconstitution inflammatory syndrome. At the end of treatment, 85.7% of cases were cured, 4 relapsed (11.4%). One year survival was 91.4%; 3 individuals died from TB (8.6%). 74.3% of the patients had more than 200 CD4+TC, in 57.1% the PVL was less than 1,000 copies/mL, 11 individuals had undetectable PVL (31.4%) a year after the diagnosis of TB. The proportions of cases with PVL ‹1,000 copies/mL a year after was not related to the time when highly active antiretroviral therapy (HAART) was started.
Conclusions: Immunological reconstitution and viraemia control were possible in Cuban HIV-positive patients infected with TB within the context of HAART.

REFERENCES

1. Brewer TF, Heymann SJ. Long time due: reducing tuberculosis mortality in the 21st century. Arch Med Res 2005;36:617-621.

2. Corbett EL, Marston B, Churchyard GJ, de Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006;367:926-937.

3. Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006;367:944-945.

4. MINSAP. Dirección Nacional de Estadísticas. Cuadro Epidemiológico Nacional, Cuba, 2005.

5. Pérez ÁJ, Pérez CD, González NI, Díaz JM, Millán MJC, Orta GM. Pautas cubanas para el tratamiento antirretroviral en los pacientes con VIH/SIDA. La Habana: MINSAP;2004.

6. Bouza JY, Reyes CA, Pentón L, León SC, Bouza JY. Evaluación de la respuesta clínica e inmunológica a la TARGA en enfermos SIDA de dos provincias cubanas. Rev Cubana Med Trop 2006;58:73-84.

7. Reyes CA, Mosquera FMA, Bouza JY, Pérez ÁJ, Hernández V, Jam MBC. Impacto de la TARVAE en la respuesta clínica e inmuno-virológica en enfermos SIDA. Cienfuegos 2001-2005. Rev Cubana Med Trop 2007 (en prensa).

8. Center for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;(RR-17):1-19.

9. Dotres MC, Pérez GR, Santín PM, Marrero FA, editores. Programa Nacional de Control de la Tuberculosis. La Habana: Ciencias Médicas;1999.p.15,72-73.

10. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. WHO/HTM/TB/2005.349. Geneva: World Health Organization; 2005.

11. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial. Lancet 2000;356:1470-1474.

12. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.

13. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002;162:97-99.

14. Reyes CA, Capó de Paz V, Díaz JM, Pérez AJ, Bouza JY. Tuberculosis y SIDA en Cuba. Estudio de dos series de casos. Rev Inst Nal Enf Resp Mex 2006;19: 16-27.

15. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006;100:415-431.

16. El-Sadr WM, Perlman DC, Denning E, Matts JR, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with Human Immunodeficiency Virus: difference in study outcomes. Clin Infect Dis 2001;32:623-632.

17. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16:75-83.

18. Reyes CA, Capó de Paz V, Díaz JM, Pérez AJ, Bouza JY. Supervivencia a los tres años del diagnóstico de 72 casos con tuberculosis y SIDA en la era pre-TARVAE en Cuba. Rev Inst Nal Enf Resp Mex 2006;19:113-121.

19. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007;21:335-341.

20. Díaz JM, González NI, Saladrigas SC, Pérez AJ, Millán MJC, Valdivia AJA. La coinfección de la tuberculosis y el HIV en Cuba. Rev Cubana Med Trop 1996; 48:214-217.

21. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007;11:78-84.

22. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006;193:1437-1440.

23. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005;19:1113-1124.

24. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007;44:229-234.